Incidence of Sturge-Weber syndrome and associated ocular involvement in Olmsted County, Minnesota, United States.
Conclusions: SWS affects approximately 0.19/100,000/year in Olmsted County. Early diagnosis, intervention, lifelong follow-up, and multidisciplinary approach should be used to optimize systemic and ocular outcomes. PMID: 32233696 [PubMed - as supplied by publisher]
Authors: Bell JA, Spencer TR Abstract Peripheral intravenous catheters are frequently used devices in emergency departments. Many patients now present with difficult anatomy and are labeled as difficult intravenous access patients. A common technology to address this challenge is ultrasound. While studies have examined the ability to train emergency staff, few have addressed how this should be done and the outcomes associated with such training. No studies were found with dedicated vascular access specialist teams in emergency departments. An emergency department vascular access specialist team was formed at a hosp...
Publication date: Available online 2 June 2020Source: Journal of American Association for Pediatric Ophthalmology and StrabismusAuthor(s): Geoffrey Collett, Abdelrahman M. Elhusseiny, Christina Scelfo, Mary C. Whitman, Deborah K. VanderVeen
Publication date: April 2020Source: Journal of American Association for Pediatric Ophthalmology and Strabismus, Volume 24, Issue 2Author(s):
On the heels of studies showing hydroxychloroquine doesn't help patients in the hospital with Covid-19, a new study -- the first of its kind -- shows the drug doesn't work to prevent infection with the virus, either.
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
Researchers say that a malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in health workers and others closely exposed to people with the disease
The first carefully controlled trial of hydroxychloroquine given to people exposed to the coronavirus did not show any benefit.
U.S. President Donald Trump had no side effects from a two-week course of hydroxychloroquine, an anti-malaria drug that can cause heart problems, after using it as a preventive measure against the coronavirus, his White House physician said on Wednesday.
The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus, the New York Times reported on Wednesday, citing senior officials.